학술논문
IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
Document Type
Article
Author
Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew ; Schuster, Stephen J ; Assouline, Sarit ; Giri, Pratyush ; Kuruvilla, John ; Canales, Miguel ; Dietrich, Sascha ; Fay, Keith ; Ku, Matthew ; Nastoupil, Loretta ; Wei, Michael C ; Yin, Shen ; Doral, Michelle Y ; Li, Chi-Chung ; Huang, Huang ; Negricea, Raluca ; Penuel, Elicia ; O'Hear, Carol ; Bartlett, Nancy L
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S387-S387
Subject
Language
ISSN
2152-2650